Metabolic Solutions Development
Kalamazoo, US · Delaware LLC
Metabolic Solutions Development Company (MSDC) is a drug discovery and development company investigating new molecular targets and developing therapeutics for metabolic diseases linked to age-related mitochondrial dysfunction, particularly insulin resistance and type 2 diabetes.
Founders & leadership
GC
Gerard ColcaCo-founder
RK
Rolf KletzienCo-founder
GC
Gerald CallahanExecutive
SB
Stephen BenoitExecutive
AS
Angeline ShashloExecutive
JV
James VanderlugtExecutive
Board
WP
William ParfetBoard director
MO
Mark OlesnavageBoard director
JS
Jim SchultzBoard director
MJ
Michael JandernoaBoard director
RZ
Robert ZerbeBoard director
Reported raises · per SEC filings
Form D private placements$16.4M disclosed across 3 rounds · 2012–2019
▶$200KraisedFeb 2019 · 15 investors · PharmaceuticalsRule 506(b)
▶$200KraisedFeb 2019 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael JandernoaDirector
- James VanderlugtExecutive Officer
- Gerard ColcaExecutive Officer, Director
- Robert ZerbeDirector
- Mark OlesnavageExecutive Officer, Director
- Rolf KletzienExecutive Officer, Director
- Angeline ShashloExecutive Officer
- Gerald CallahanExecutive Officer, Director
- Sandi DoctorDirector
- Stephen BenoitDirector
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Jan 2019
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$16.1MraisedSep 2015 · 30 investors · PharmaceuticalsRule 506(b)
▶$16.1MraisedSep 2015 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gerald CallahanExecutive Officer, Director
- William ParfetDirector
- Stephen BenoitExecutive Officer, Director
- Mark OlesnavageExecutive Officer, Director
- Angeline ShashloExecutive Officer
- Robert ZerbeDirector
- James VanderlugtExecutive Officer
- Gerard ColcaExecutive Officer, Director
- Jim SchultzDirector
- Michael JandernoaDirector
- Rolf KletzienExecutive Officer, Director
- Offering amount
- $18.4M
- Amount sold
- $16.1M
- First sale
- Aug 2012
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$98.2KraisedFeb 2014 · 2 investors · PharmaceuticalsRule 506(b)
▶$98.2KraisedFeb 2014 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jim SchultzDirector
- Angeline ShashloExecutive Officer
- Rolf KletzienExecutive Officer, Director
- Gerald CallahanExecutive Officer, Director
- Michael JandernoaDirector
- James VanderlugtExecutive Officer
- Stephen BenoitExecutive Officer, Director
- Mark OlesnavageExecutive Officer, Director
- Gerard ColcaExecutive Officer, Director
- William ParfetDirector
- Offering amount
- $98.2K
- Amount sold
- $98.2K
- First sale
- Feb 2014
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Medscape17 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Diabetes14 shared keywordsA nonprofit organization that provides educational resources and information about prediabetes, including prevention strategies and lifestyle management for Americans at risk of developing type 2 diabetes.
Osmosis10 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
Companies competing with Metabolic Solutions Development for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $122K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2011 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2010 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2009 | $140.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2009 | $139.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Metabolic Solutions Development do?
- Metabolic Solutions Development Company (MSDC) is a drug discovery and development company investigating new molecular targets and developing therapeutics for metabolic diseases linked to age-related mitochondrial dysfunction, particularly insulin resistance and type 2 diabetes.
- Who founded Metabolic Solutions Development?
- Metabolic Solutions Development was founded by Gerard Colca, Rolf Kletzien.
- How much funding has Metabolic Solutions Development raised?
- Metabolic Solutions Development has disclosed $16.4M raised across 3 rounds.
- Where is Metabolic Solutions Development headquartered?
- Metabolic Solutions Development is headquartered in Kalamazoo, US.